A live audio webcast of the presentation will be accessible through the company's investor relations section of the website at www.cutera.com. An archived edition of the presentation, as well as a replay of the audio section, will be available until Wednesday, December 30, 2009 on the Investor Relations section of the company's website at http://www.cutera.com.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

http://www.financialwire.net

About Cutera, Inc.

Brisbane, California-based Cutera is a leading provider of laser and other light-based aesthetic systems for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. For more information, call 1-888-4CUTERA or visit www.cutera.com.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Cutera, Inc.

CONTACT:  Cutera, Inc.
Ron Santilli, Chief Financial Officer
415-657-5500
Integrated Corporate Relations, Inc.
Investor Relations
John Mills
310-954-1100
john.mills@icrinc.com

In a press release out on November 23, Cutera to Present at the Piper Jaffray 21st Annual Health Care Conference

BRISBANE, Calif., Nov 23, 2009 -- Cutera, Inc. (Nasdaq:CUTR), a leading provider of laser and other light-based aesthetic systems for practitioners worldwide, announced today that Kevin Connors, the Company's Chief Executive Officer, will be presenting at the Piper Jaffray 21st Annual Health Care Conference on December 2, 2009 at 1:30 p.m. ET., at the New York Palace Hotel in New York, NY.

About Cutera, Inc.

Brisbane, California-based Cutera is a leading provider of laser and other light-based aesthetic systems for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. For more information, call 1-888-4CUTERA or visit www.cutera.com.

Exceed Company Ltd. (NASDAQ: EDS) trading at $10.05 per share on trading volume of 43,000 shares.

In a press release out on November 23, Exceed Company Ltd. Announces Intent to Offer Program for Early Cashless Exercise of Warrants Through Ordinary Share Exchange

BEIJING, Nov 23, 2009 -- Exceed Company Ltd. ("Exceed" or the "Company") (NASDAQ: EDS), announced today that the Company intends to offer the holders of all 10,890,000 outstanding warrants (the "Warrants") the opportunity, for a limited time, to acquire ordinary shares of the Company (the "Ordinary Shares") through warrant for share exchange. Exceed intends to modify the terms of the Warrants to permit, instead of paying the purchase price of $5.25 in cash, the exchange of 3.96 Warrants for one Ordinary Share. The exchange ratio was determined by the board of directors of Exceed based on the ratio of the actual average daily closing prices of the Ordinary Shares and Warrants on NASDAQ for the period of November 9, 2009 to November 13, 2009.

ABOUT EXCEED COMPANY LTD

Exceed Company Ltd. designs, develops and engages in wholesale of footwear, apparel and accessories under its own brand, XIDELONG, in China. It is one of the leading domestic sports and leisurewear brands in China in terms of market share by sales revenue. Since operations began in 2002, Exceed has experienced significant growth in the mass market concentrated in the second and third tier cities in China and has established a market leading position as one of the top five Chinese sportswear brands. Exceed has three principal categories of products: (i) footwear, which comprises running, leisure, basketball, skateboarding and canvas footwear, (ii) apparel, which mainly comprises sports tops, pants, jackets, track suits and coats, and (iii) accessories, which mainly comprise bags, socks, hats and caps. Exceed Company Ltd. currently trades on Nasdaq under the symbols "EDS", "EDSWW" and "EDSUU".

Riverbed Technology (NASDAQ: RVBD) trading at $21.50 on a volume of 167,215 shares

In a press release out on November 23, Stena Drills Down to Reduce Bandwidth and IT Infrastructure Costs With Riverbed Steelhead Appliances

WAN Optimization Solution Cuts Costs While Improving Employee Productivity and Collaboration Over Satellite Network

SAN FRANCISCO, CA, Nov 23, 2009 -- Riverbed Technology (NASDAQ: RVBD), the IT infrastructure performance company for networks, applications and storage, today announced that Stena Drilling, a leading global provider and operator of offshore drilling rigs and drillships, has deployed Riverbed(R) Steelhead(R) appliances and Steelhead Mobile at various onshore and offshore locations worldwide. The deployment has allowed Stena to avoid both a costly bandwidth upgrade as well as additional investment in IT infrastructure. At the same time, Stena has seen a 30x improvement in file download times and enhanced staff collaboration.

About Riverbed

Riverbed Technology is the IT infrastructure performance company. The Riverbed family of wide area network (WAN) optimization solutions liberates businesses from common IT constraints by increasing application performance, enabling consolidation, and providing enterprise-wide network and application visibility -- all while eliminating the need to increase bandwidth, storage or servers. Thousands of companies with distributed operations use Riverbed to make their IT infrastructure faster, less expensive and more responsive. Additional information about Riverbed (NASDAQ: RVBD) is available at www.riverbed.com.

Seattle Genetics, Inc. (Nasdaq: SGEN) trading at $9.44 on a volume of 70,148 shares

In a press release out on November 23, Seattle Genetics and Agensys, an Affiliate of Astellas, Expand Antibody-Drug Conjugate Collaboration

BOTHELL, Wash. & SANTA MONICA, Calif., Nov 23, 2009 -- Seattle Genetics, Inc. (Nasdaq: SGEN) and Agensys, Inc., an affiliate of Astellas, announced today an expansion of the companies' antibody-drug conjugate (ADC) collaboration. Under the amended agreement, Agensys will pay a $12 million fee for exclusive rights to ADC licenses against additional antigen targets. Seattle Genetics also receives an option to co-develop another ADC at the time of investigational new drug (IND) submission.

About Seattle Genetics

Seattle Genetics is a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company's lead product candidate, brentuximab vedotin (SGN-35), is in a pivotal trial under a special protocol assessment with the FDA. Brentuximab vedotin is empowered by Seattle Genetics' proprietary ADC technology comprising highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. In addition, Seattle Genetics has four other product candidates in ongoing clinical trials: lintuzumab (SGN-33), dacetuzumab (SGN-40), SGN-70 and SGN-75. Dacetuzumab is being developed under a worldwide collaboration with Genentech (a wholly owned member of the Roche Group). Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech; Bayer; CuraGen, a subsidiary of Celldex Therapeutics; Progenics; Daiichi Sankyo; MedImmune, a subsidiary of AstraZeneca; and Millennium: The Takeda Oncology Company, as well as an ADC co-development agreement with Agensys, an affiliate of Astellas Pharma. More information can be found atwww.seattlegenetics.com.

Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.

Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm

CONTACT: Xtremepicks.com e-mail: Info@xtremepicks.com WWW: http://www.Xtremepicks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

  --  Revenue increased by 4% to $12.2 million, compared to $11.7
      million in the second quarter of 2009.
  --  Gross margin improved to 60%, compared to 56% in the second
      quarter of 2009.
  --  Cash from operations was approximately breakeven.
  --  Net loss was $13.5 million, or $1.01 per diluted share, which
      included a $12.3 million, or $0.92 per diluted share, non-cash
      tax charge, to establish a valuation allowance against our U.S.
      deferred tax assets.

Kevin Connors, President and CEO of Cutera, stated, "We experienced an improvement in our third quarter 2009 revenue. It is important to note that, in our industry, traditionally the third quarter is seasonally softer than the second quarter. Our customers continue to experience demand for our products from end users, however, many of our current and prospective customers remain reluctant to make major capital equipment purchases or are unable to obtain financing during these challenging economic times. In the current market environment, we believe that the core market of dermatologists, plastic surgeons and other established medical offices provides us with the best opportunities in our industry. Therefore, we are actively refocusing our sales, marketing and new product development efforts on this market segment.

"We have significantly improved our gross margin and operating expenses, when compared to the second quarter of 2009. We believe these improvements are resulting from our first half restructuring efforts, which incorporated many cost reduction measures. We remain focused on increasing revenue levels and to leverage our business model, which we expect will result in increased profits. As a result of the recent restructuring activities, we believe our current operating model will result in breakeven profit performance when revenue is in the $14.0 - $15.0 million range."

Mr. Connors concluded, "While the near-term prospects for our industry are difficult to predict due to the continuing economic uncertainty, we believe that our worldwide distribution network, strong balance sheet with $104.2 million in cash and investments -- with no debt, a broad portfolio of products, and various research and development projects underway -- offer continuing, long-term opportunities for our company."

Conference Call:

The conference call to discuss these results is scheduled to begin at 2:00 p.m. PT (5:00 p.m. ET) on November 2, 2009. The call will be broadcast live over the Internet hosted at the Investor Relations section of Cutera's website at www.cutera.com, and will be archived online within one hour of its completion and continue through 8:59 p.m. PT (11:59 p.m. ET) on November 16, 2009. In addition, you may call (877) 941-1427 to listen to the live broadcast. Participating in the call will be Kevin Connors, President and Chief Executive Officer, and Ron Santilli, Executive Vice President and Chief Financial Officer.

About Cutera, Inc.

Brisbane, California-based Cutera is a leading provider of laser and other light-based aesthetic systems for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. For more information, call 1-888-4CUTERA or visit www.cutera.com.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning Cutera's ability to grow its business, increase revenue, manage costs and expenses, generate additional cash, regain profitability, develop and commercialize existing and new products and applications, improve the performance of its worldwide sales and distribution network, and statements regarding long-term prospects and opportunities are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Cutera's actual results to differ materially from the statements contained herein. Potential risks and uncertainties that could affect Cutera's business and cause its financial results to differ materially from those contained in the forward-looking statements include the global economic crisis, which may reduce consumer demand for its products, cause potential customers to delay their purchase decisions and make it more difficult for some potential customers to obtain credit financing; its ability to increase revenue, manage costs and expenses and improve sales productivity and performance worldwide; its ability to successfully develop and acquire new products and applications and market them to both its installed base and new customers; the length of the sales cycle process; unforeseen events and circumstances relating to its operations; government regulatory actions; and those other factors described in the section entitled, "Risk Factors," in its most recent Form 10-Q as filed with the Securities and Exchange Commission on November 2, 2009. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. Cutera's third quarter ended September 30, 2009 financial performance, as discussed in this release, is preliminary and unaudited, and subject to adjustment.

                             CUTERA, INC.
                 CONDENSED CONSOLIDATED BALANCE SHEETS
                            (in thousands)
                              (unaudited)

                         September 30,     June 30,       December 31,
                             2009            2009             2008
                         -------------   -------------   -------------

 Assets
 Current assets:
  Cash and cash
   equivalents            $     34,302    $     35,445    $     36,540
  Marketable
   investments                  62,572          61,857          60,653
  Accounts
   receivable, net               2,635           2,828           5,792
  Inventories                    7,884           8,702           9,927
  Deferred tax asset               244           4,652           4,257
  Other current
   assets and
   prepaid expenses              2,644           4,548           1,771
                         -------------   -------------   -------------
     Total current
      assets                   110,281         118,032         118,940

 Property and
  equipment, net                   939           1,101           1,357
 Long-term
  investments                    7,339           7,640           9,627
 Intangibles, net                  877             926           1,025
 Deferred tax asset,
  net of current
  portion                           --           6,165           6,527
                         -------------   -------------   -------------
     Total assets         $    119,436    $    133,864    $    137,476
                         =============   =============   =============

 Liabilities and
  Stockholders' Equity
 Current liabilities:
  Accounts payable        $      1,212    $      1,127    $      1,690
  Accrued liabilities
                                 7,281           7,737           8,848
  Deferred revenue

                                 6,295           6,506           6,758
                         -------------   -------------   -------------
     Total current
      liabilities               14,788          15,370          17,296

 Deferred rent                   1,548           1,603           1,713
 Deferred revenue,
  net of current
  portion                        2,331           3,134           4,907
 Income tax
  liability                        882           1,367           1,452
                         -------------   -------------   -------------
     Total
      liabilities               19,549          21,474          25,368
                         -------------   -------------   -------------

 Stockholders' equity:
  Common stock                      13              13              13
  Additional
   paid-in capital              84,148          82,985          80,318
  Retained earnings             17,247          30,741          31,410
  Accumulated other
   comprehensive
   income (loss)                (1,521)         (1,349)            367
                         -------------   -------------   -------------
     Total
      stockholders'
      equity                    99,887         112,390         112,108
                         -------------   -------------   -------------
 Total liabilities
  and stockholders'
  equity                  $    119,436    $    133,864    $    137,476
                         =============   =============   =============


                              CUTERA, INC.
            CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                 (in thousands, except per share data)
                              (unaudited)

                                     Three Months Ended
                         ---------------------------------------------
                         September 30,     June 30,      September 30,
                              2009           2009            2008
                         -------------   -------------   -------------

 Net revenue              $     12,171    $     11,665    $     19,110
 Cost of revenue                 4,910           5,130           7,823
                         -------------   -------------   -------------

     Gross profit                7,261           6,535          11,287
                         -------------   -------------   -------------
 Operating expenses:
   Sales and marketing           5,112           6,071           8,076
   Research and
    development                  1,684           1,495           1,828
   General and
    administrative               2,121           3,616           2,583
                         -------------   -------------   -------------

     Total operating
      expenses                   8,917          11,182          12,487
                         -------------   -------------   -------------
 Loss from operations           (1,656)         (4,647)         (1,200)
 Interest and other
  income, net                      288             511             733
 Other-than-temporary
  impairments on
  long-term
  investments                       --              --          (2,372)
                         -------------   -------------   -------------
 Loss before income
  taxes                         (1,368)         (4,136)         (2,839)
 Provision (benefit)
  for income taxes              12,126          (1,772)            (86)
                         -------------   -------------   -------------
 Net loss                      (13,494)         (2,364)         (2,753)
                         =============   =============   =============

 Net loss per share:
      Basic               $      (1.01)   $      (0.18)   $      (0.22)
                         =============   =============   =============
      Diluted             $      (1.01)   $      (0.18)   $      (0.22)
                         =============   =============   =============

 Weighted-average
  number of shares
  used in per share
  calculations:
      Basic                     13,382          13,317          12,780
                         =============   =============   =============
      Diluted                   13,382          13,317          12,780
                         =============   =============   =============


                              CUTERA, INC.
            CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                            (in thousands)
                              (unaudited)


                                     Three Months Ended
                         ---------------------------------------------
                         September 30,      June 30,     September 30,
                             2009             2009           2008
                         -------------   -------------   -------------
 Cash flows from
  operating activities:
 Net loss                 $    (13,494)   $     (2,364)   $     (2,753)
 Adjustments to
  reconcile net loss
  to net cash used
  in operating
  activities:
   Stock-based
    compensation                   895           1,456           1,326
   Tax benefit
    (deficit) from
    stock-based
    compensation                   111             (86)            100
   Depreciation and
    amortization                   211             225             220
   Provision for
    excess and
    obsolete
    inventories                  (256)             130             (78)
   Other-than-
    temporary
    impairments on
    long-term
    investments                     --              --           2,372
   Change in
    allowance for
    doubtful accounts               (3)            498              60
   Change in
    deferred tax
    asset and
    deferred tax
    liability                   10,506             139             168
 Changes in assets
  and liabilities:
   Accounts receivable             196           1,936           2,611
   Inventories                   1,074           1,014             (66)
   Other current
    assets and
    prepaid expenses             2,539          (1,054)            173
   Accounts payable                 85            (408)            206
   Accrued liabilities           (575)            (429)         (1,634)
   Deferred rent                    64             (55)             19
   Deferred revenue             (1,014)           (957)            336
   Income tax
    liability                     (485)            (54)           (191)
                         -------------   -------------   -------------

     Net cash
      provided by
      (used in)
      operating
      activities                  (146)             (9)          2,869
                         -------------   -------------   -------------
 Cash flows from
  investing
  activities:
 Acquisition of
  property and
  equipment                         --             (36)           (317)
 Proceeds from sales
  of marketable and
  long-term
  investments                    4,442           9,774           8,774
 Proceeds from
  maturities of
  marketable
  investments                    8,315           1,100           8,480
 Purchase of
  marketable and
  long-term
  investments                  (13,911)        (11,342)        (13,590)
                         -------------   -------------   -------------

     Net cash
      provided by
      (used in)
      investing
      activities                (1,154)           (504)          3,347
                         -------------   -------------   -------------

 Cash flows from
  financing activities:
 Proceeds from
  exercise of stock
  options and employee
  stock purchase plan              157             165              3
                         -------------   -------------   -------------

     Net cash provided
      by financing
      activities                   157             165              3
                         -------------   -------------   -------------

 Net increase
  (decrease) in cash
  and cash equivalents          (1,143)           (348)          6,219
 Cash and cash
  equivalents at
  beginning of period           35,445          35,793          20,464
                         -------------   -------------   -------------
 Cash and cash
  equivalents at end
  of period               $     34,302    $     35,445    $     26,683
                         =============   =============   =============


                              CUTERA, INC.
                    CONSOLIDATED REVENUE HIGHLIGHTS
                (in thousands, except percentage data)
                              (unaudited)

                                     Three Months Ended
                         ---------------------------------------------
                         September 30,      June 30,     September 30,
                              2009            2009            2008
                         -------------   -------------   -------------

 Revenue By Geography:
 United States           $  4,825  40%   $  4,551  39%   $  9,498  50%
 International              7,346  60%      7,114  61%      9,612  50%
                         --------        --------        --------
                         $ 12,171        $ 11,665        $ 19,110
                         ========        ========        ========

 Revenue By Product
  Category:
 Products                $  6,322  52%   $  5,664  49%   $ 12,920  68%
 Product upgrades           1,352  11%      1,201  10%      1,948  10%
 Service                    3,210  26%      3,397  29%      2,920  15%
 Titan refills              1,287  11%      1,403  12%      1,322   7%
                         --------        --------        --------
                         $ 12,171        $ 11,665        $ 19,110
                         ========        ========        ========

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Cutera, Inc.

CONTACT:  Cutera, Inc.
Ron Santilli, Chief Financial Officer
415-657-5500
Integrated Corporate Relations, Inc.
Investor Relations
John Mills
310-954-1100
john.mills@icrinc.com